What the CDC guidance actually covers
The CDC has specifically noted increased risk of carbapenem-resistant Enterobacteriaceae (CRE) and other resistant organisms associated with international healthcare exposure in certain regions and facility types — the guidance recommends screening for patients who received inpatient care abroad, particularly following hospitalization in regions with documented higher resistance prevalence.
Why facility quality is the actual variable, not country alone
Infection control protocol — sterile technique, antibiotic stewardship, prophylactic antibiotic timing — is a facility-level practice, not a national trait. At JCI-accredited facilities specifically, infection rates run comparable to US benchmarks per available data; the resistance concern concentrates more heavily around lower-oversight facilities and certain high-risk regions globally.
What to ask before booking
- Does the facility follow documented antibiotic stewardship protocols?
- What's the facility's infection control accreditation status specifically?
- Should you be screened for resistant organisms after your specific trip, based on your destination and procedure type?
Ask your domestic physician about post-trip screening specifically if you're uncertain — this is a reasonable, low-cost precaution regardless of destination. Facilities via colombiacosmeticsurgery.com and colombiadentist.co that take infection control seriously should be able to speak to their specific protocols directly.
The Takeaway
This is a facility-level and region-level concern, not a blanket reason to avoid international care — verify the specific facility's infection control track record and ask your domestic physician about screening if appropriate.